Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Escitalopram

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Escitalopram

Kristen Landy et al.
Free Books & Documents

Excerpt

Escitalopram, the (S)-enantiomer of citalopram, is a highly selective serotonin reuptake inhibitor. Escitalopram is approved by the U.S. Food and Drug Administration (FDA) for treating major depressive disorder (unipolar) in adults and adolescents (ages 12 to 17) for both acute and maintenance phases. The FDA recently approved escitalopram for the treatment of generalized anxiety disorder in both adults and children aged 7 and older. Escitalopram is also used off-label for conditions such as social anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and the management of vasomotor symptoms associated with menopause. Safe and effective treatment of escitalopram requires an understanding of its potential adverse effects and drug interactions. This activity outlines the clinical applications, mechanisms of action, possible adverse effects, and drug interactions of escitalopram to help interprofessional healthcare providers direct patient therapy in treating various conditions. This activity also emphasizes the importance of vigilant monitoring and making informed decisions by healthcare professionals throughout escitalopram therapy, facilitating early detection and intervention to ensure patient safety and provide optimal care.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Kristen Landy declares no relevant financial relationships with ineligible companies.

Disclosure: Alan Rosani declares no relevant financial relationships with ineligible companies.

Disclosure: Ryan Estevez declares no relevant financial relationships with ineligible companies.

References

    1. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. - PMC - PubMed
    1. Strawn JR, Moldauer L, Hahn RD, Wise A, Bertzos K, Eisenberg B, Greenberg E, Liu C, Gopalkrishnan M, McVoy M, Knutson JA. A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder. J Child Adolesc Psychopharmacol. 2023 Apr;33(3):91-100. - PubMed
    1. Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E, Larsen K. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. Eur Neuropsychopharmacol. 2016 Jun;26(6):1062-9. - PubMed
    1. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. - PubMed
    1. Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. J Okla State Med Assoc. 2017 May;110(5):272-274. - PMC - PubMed

Publication types

LinkOut - more resources